TransCode Therapeutics closed at $1.60 on Nov 4, up 1.91%, 87.0% below its 52-week closing high. Volume of 7.1K shares was 0.22× its 20-day average (below normal).
Split-adjusted performance: -10.1% over one month, -78.7% over six months.
Short interest was 55.0K shares at the Oct 15 settlement, up 5.6% from the prior report (8.1% of float, 1.4 days to cover).
No reported quarters with price history yet.
Percentile among 420 companies (100 = best)
Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| RNAZTransCode Therapeutics | $1.60 | +1.91% | −78.7% | — | — | — | $27.1M | |
| NXTCNextCure | $5.85 | −1.02% | −45.4% | — | — | — | $26.8M | Compare |
| ABVCABVC BioPharma | $1.00 | +1.51% | −9.1% | — | — | — | $26.7M | Compare |
| AARDAardvark Therapeutics | $1.26 | +2.44% | −78.6% | — | — | — | $27.6M | Compare |
| FLNAFilana Therapeutics | $0.5720 | −3.75% | — | — | — | — | $27.6M | Compare |
| BCTXBriacell Therapeutics | $3.19 | +5.98% | −23.1% | — | — | — | $27.9M | Compare |
| BYSIBeyondSpring | $0.6790 | +9.34% | −56.2% | — | — | — | $27.9M | Compare |
| CELUCelularity | $0.8088 | −1.02% | −13.0% | −5.3% | 10.1% | — | $26.2M | Compare |
| ACETAdicet Bio | $3.10 | −2.21% | −63.7% | — | — | — | $29.0M | Compare |
TransCode Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of RNA-based therapeutics and immuno-oncology treatments for cancer. The company's lead candidate, TTX-MC138, targets microRNA-10b and has completed a Phase 1a clinical trial, while it is also advancing additional product candidates, including a cancer vaccine and an oncolytic immunotherapy platform.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
